What is TORPIDO2?

The TORPIDO2 study is a clinical trial that compares 2 commonly used levels of oxygen for respiratory care in the delivery room for babies born at less than 29 weeks gestation to see if one has more benefits without increasing risks in the short and the long term.

What are we trying to find out?

The main question we are trying to answer is whether lower or higher oxygen in the delivery room is better when comparing survival without major disability at 2 years old.

We will also compare short term hospital outcomes such as bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), necrotising enterocolitis (NEC), sepsis, patent ductus arteriosus (PDA), duration of hospital stay, all-cause mortality, respiratory morbidity and complication, spontaneous intestinal perforation and brain injury.

Coordination, Sponsorship and Funding

This multi-centre trial is coordinated by the NHMRC Clinical Trials Centre (CTC), University of Sydney and is sponsored by the University of Sydney. Funding is provided by the National Health and Medical Research Council (NHMRC).

This trial is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR), registration number 12615000115538.

Below is a short introduction to the trial presented by Melinda Cruz, Founder and CEO of Miracle Babies Foundation.


TORPIDO2 resources

Parent resources

Miracle Babies Foundation


Staff resources

Visit the TORPIDO2-Members Only page (password protected). Authorised users only.